Sign inJoin waitlistJoin the waitlist

Joanna Rhodes

Director, Lymphoma Program · Rutgers Health

Credentials: · · · · · ·

History

Lymphoma Division · Rutgers Health
Present
Rutgers Health
Present
Rutgers Health
Present

Hematology and Medical Oncology
2016–2019
Internal Medicine
New York Presbyterian Hospital
2013–2016
Boston University
Renaissance School of Medicine at Stony Brook University
2009–2013
Wesleyan University
2005–2009

Research

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia
New England Journal of Medicine · 2023 · 204 citations
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
Haematologica · 2018 · 149 citations
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127
Science · 2024 · 133 citations

Anthony Mato
19 papers
Lindsey Roeker
17 papers · 7 as a fellow
Mazyar Shadman
16 papers
CC
Catherine Coombs
15 papers · 7 as a fellow
Stephen Schuster
15 papers
Alan Skarbnik
13 papers
Chaitra Ujjani
13 papers
Nicole Lamanna
13 papers
Brian Hill
11 papers
Danielle Brander
11 papers
Jacqueline Barrientos
11 papers
John Allan
11 papers

Clinical trials

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
Site PI · Recruiting · Phase 3
Acrotech Biopharma Inc.
2023–2030
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
Site PI · Recruiting · Phase 2
Timothy Voorhees
2023–2027
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2021–2028